The London Company Income Equity portfolio returned 12.3% year-to-date vs. a 14.4% increase in the Russell 1000 Value Index.

Germany’s Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206 ...

Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...

We recently compiled a list of the Jim Cramer Discusses These 11 Stocks & Finds Few Reasons To Sell. In this article, we are ...

It is movie time as Captain America has a Brave New World, kind of. And believe it or not, I am still in love with Bridget ...

New York Gov. Kathy Hochul (D) weighed in on the recent extradition order in place for a New York doctor who allegedly sent ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

"We think it's based on, you know, the overall data package we've been able to generate, and the additional follow on data that we've provided the agency," the CEO continued. So we look forward to ...

Green Shipping Corridors: The Hurdles Ahead Under current and prospective policies from the IMO, EU, and US, the business case… Veson Nautical Opens Dubai Office Veson Nautical (Veson) opened a ...

A collection of programmes and features celebrating 100 years of the Shipping Forecast.